60 related articles for article (PubMed ID: 24531173)
21. Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
Smith CJ; Sabin CA; Youle MS; Kinloch-de Loes S; Lampe FC; Madge S; Cropley I; Johnson MA; Phillips AN
J Infect Dis; 2004 Nov; 190(10):1860-8. PubMed ID: 15499544
[TBL] [Abstract][Full Text] [Related]
22. Total lymphocyte count is a reliable surrogate marker for CD4 cell counts after the first year of antiretroviral therapy: data from an Indonesian cohort study.
de Jong MA; Wisaksana R; Meijerink H; Indrati A; van de Ven AJ; Alisjahbana B; van Crevel R
Trop Med Int Health; 2012 May; 17(5):581-3. PubMed ID: 22364582
[TBL] [Abstract][Full Text] [Related]
23. Comparative analysis of T-cell turnover and homeostatic parameters in HIV-infected patients with discordant immune-virological responses to HAART.
Marchetti G; Gori A; Casabianca A; Magnani M; Franzetti F; Clerici M; Perno CF; Monforte Ad; Galli M; Meroni L
AIDS; 2006 Aug; 20(13):1727-36. PubMed ID: 16931937
[TBL] [Abstract][Full Text] [Related]
24. HIV-1-infected children on HAART: immunologic features of three different levels of viral suppression.
Zaccarelli-Filho CA; Ono E; Machado DM; Brunialti M; Succi RC; Salomão R; Kallás EG; de Moraes-Pinto MI
Cytometry B Clin Cytom; 2007 Jan; 72(1):14-21. PubMed ID: 17041945
[TBL] [Abstract][Full Text] [Related]
25. Immunophenotype of HIV+ patients during CD4 cell-monitored treatment interruption: role of the IL-7/IL-7 receptor system.
Nemes E; Lugli E; Nasi M; Ferraresi R; Pinti M; Bugarini R; Borghi V; Prati F; Esposito R; Cossarizza A; Mussini C
AIDS; 2006 Oct; 20(16):2021-32. PubMed ID: 17053348
[TBL] [Abstract][Full Text] [Related]
26. CD4 lymphocyte percentage predicts disease progression in HIV-infected patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 lymphocytes/mm3.
Hulgan T; Raffanti S; Kheshti A; Blackwell RB; Rebeiro PF; Barkanic G; Ritz B; Sterling TR
J Infect Dis; 2005 Sep; 192(6):950-7. PubMed ID: 16107946
[TBL] [Abstract][Full Text] [Related]
27. CD4 T cell count reconstitution in HIV controllers after highly active antiretroviral therapy.
Okulicz JF; Grandits GA; Weintrob AC; Landrum ML; Ganesan A; Crum-Cianflone NF; Agan BK; Marconi VC
Clin Infect Dis; 2010 Apr; 50(8):1187-91. PubMed ID: 20218878
[TBL] [Abstract][Full Text] [Related]
28. Host, disease, and antiretroviral factors are associated with normalization of the CD4:CD8 ratio after initiating antiretroviral therapy.
Winston A; Jose S; Fisher M; Walsh J; Nelson M; Gilson R; Post F; Johnson M; Leen C; Chadwick D; Hay P; Pritchard J; Tariq A; Sabin C;
J Allergy Clin Immunol; 2015 Dec; 136(6):1682-1685.e1. PubMed ID: 26253341
[No Abstract] [Full Text] [Related]
29. Surrogate markers as a guide to evaluate response to antiretroviral therapy.
De Milito A; Titanji K; Zazzi M
Curr Med Chem; 2003 Mar; 10(5):349-65. PubMed ID: 12570696
[TBL] [Abstract][Full Text] [Related]
30. HAART and host: balancing the response to HIV-1. Highly active antiretroviral therapy.
Morris K
Lancet; 1998 Nov; 352(9141):1686. PubMed ID: 9853453
[No Abstract] [Full Text] [Related]
31. The Revival of an "Old" Marker: CD4/CD8 Ratio.
Bruno G; Saracino A; Monno L; Angarano G
AIDS Rev; 2017; 19(2):81-88. PubMed ID: 28182620
[TBL] [Abstract][Full Text] [Related]
32. [Immunological and hematological aspects of HIV infection].
Delhougne B; Fillet G
Rev Med Liege; 1993 Feb; 48(2):72-80. PubMed ID: 8095351
[No Abstract] [Full Text] [Related]
33. HIV antiretroviral therapy reduces circulating surfactant protein-D levels.
Kunisaki KM; Quick H; Baker JV
HIV Med; 2011 Oct; 12(9):580-1. PubMed ID: 21951596
[No Abstract] [Full Text] [Related]
34. Immune recovery inflammatory folliculitis.
Bouscarat F; Maubec E; Matheron S; Descamps V
AIDS; 2000 Mar; 14(5):617-8. PubMed ID: 10780726
[No Abstract] [Full Text] [Related]
35. CD4/CD8 ratio: an emerging biomarker for HIV.
Serrano-Villar S; Deeks SG
Lancet HIV; 2015 Mar; 2(3):e76-7. PubMed ID: 26424546
[No Abstract] [Full Text] [Related]
36. Imbalance in the game of T cells: What can the CD4/CD8 T-cell ratio tell us about HIV and health?
McBride JA; Striker R
PLoS Pathog; 2017 Nov; 13(11):e1006624. PubMed ID: 29095912
[No Abstract] [Full Text] [Related]
37. Immunological effects of unemployment.
Marriott D; Kirkwood BJ; Stough C
Lancet; 1994 Jul; 344(8917):269-70. PubMed ID: 7913186
[No Abstract] [Full Text] [Related]
38. Immune recovery markers in a double blind clinical trial comparing dolutegravir and raltegravir based regimens as initial therapy (SPRING-2).
Blanco JR; Alejos B; Moreno S
PLoS One; 2020; 15(1):e0226724. PubMed ID: 31945066
[TBL] [Abstract][Full Text] [Related]
39. Absolute CD4+ T cell count overstate immune recovery assessed by CD4+/CD8+ ratio in HIV-infected patients on treatment.
Milanés-Guisado Y; Gutiérrez-Valencia A; Trujillo-Rodríguez M; Espinosa N; Viciana P; López-Cortés LF
PLoS One; 2018; 13(10):e0205777. PubMed ID: 30346965
[TBL] [Abstract][Full Text] [Related]
40. For timing of HAART is less more? CD4+/CD8+ ratio and CD4+ percentage as surrogate markers for more complex immunological features.
Fogli M; Iaria M; Focá E; Giagulli C; Caccuri F; Maggi F; Torti C; Caruso A; Fiorentini S
New Microbiol; 2014 Jan; 37(1):75-80. PubMed ID: 24531173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
